Danaher initiated with a Buy at Guggenheim

Guggenheim analyst Subbu Nambi initiated coverage of Danaher (DHR) with a Buy rating and $275 price target as the firm expands its bioprocessing tools coverage. Danaher has not only built out a best-in-class bioprocessing business, it is among the top diversified global life science tools companies with “a fantastic track record of operational execution and strategic consolidation,” the analyst tells investors. The firm expects a gradual return to high-single digit bioprocessing revenue growth with “the rest of the business to follow over the next several quarters,” the analyst added.